U.S. FDA Approves TICOVAC, Pfizer’s Tick-Borne Encephalitis (TBE) Vaccine

0

Pfizer Inc. on Aug 13, 2021 announced that the U.S. Food and Drug Administration (FDA) has approved TICOVAC (tick-borne encephalitis (TBE) vaccine) for active immunization to prevent TBE in individuals 1 year of age and older.1 TICOVAC is the only FDA-approved vaccine to help protect U.S. adults and children against the TBE virus when visiting or living in TBE endemic areas. Following FDA’s approval, the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) is expected to discuss recommendations on the safe and appropriate use of TICOVAC.

“We are proud to deliver the first vaccine to help protect people in the U.S. against TBE, if they are traveling to any risk areas,” said Nanette Cocero, Ph.D., Global President, Vaccines, Pfizer. “This vaccine has helped to protect millions of people in TBE endemic regions since its first approval outside the U.S. 45 years ago. This authorization helps to ensure that people from the U.S. are also able to receive this vaccination if needed, reflecting our commitment to provide health for all.”

[the_ad id=”10542″]

TBE is a viral infection of the brain and spine, which can be transmitted to humans through the bite of an infected tick. Although TBE is not endemic in the U.S., to date, it has been identified in more than 35 countries across Europe and Asia. The European Centre for Disease Prevention and Control (ECDC) currently recommends TBE vaccination for people who live in or are traveling to risk areas.

More than 45 years of experience with the Pfizer TBE vaccine exist outside the U.S., and more than 170 million doses of the vaccine have been distributed since 1976.

[the_ad id=”10542″]

About TICOVAC (Tick-borne encephalitis vaccine)
Pfizer’s TBE vaccine, marketed under the brand names FSME-Immun and TicoVac in Europe, and TICOVAC in the U.S., is developed using a master ‘seed’ virus that is similar to the TBE virus found in nature. It is able to induce neutralizing antibodies against the natural TBE virus, as the sequence and structure of the virus subtype match those found in nature.

In clinical trials, the safety and immunogenicity of TICOVAC were assessed across two age groups (1-15 years of age and >16 years of age). In these studies, seropositivity rates were 99.5% in 1-15 year olds and 98.7-100% in adults >15 years following three doses. Clinical studies demonstrated that TICOVAC was generally well-tolerated with no unexpected adverse events or vaccine-related serious adverse events observed. The most common adverse reactions across both age groups were local tenderness, headache, local pain, fever, restlessness, fatigue, and muscle pain. Real-world studies from Austria have shown that the vaccine is 96-98.7% effective in people who have received at least three doses of the vaccine.

[the_ad id=”10542″]

About TBE
TBE is a viral infection of the brain and spine, transmitted to humans through the bite of an infected tick, and less frequently by ingestion of unpasteurized milk or milk products from infected animals. It may initially be mistaken for summer flu, but can be a serious condition with possible long-term consequences. 1 in 3 people can have long-term effects that last months or years including cognitive changes, muscle weakness or permanent paralysis, and in rare cases (0.5-2%; up to 20% in Russia), people may die. TBE can affect people of all ages who come into contact with ticks whenever they do outdoor activities in countries where ticks infected with TBE are prevalent.

[the_ad id=”10542″]

U.S. Important Safety Information for TICOVAC

  • TICOVAC should not be given to anyone with a severe allergic reaction (e.g. anaphylaxis) to any component of TICOVAC
  • Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of TICOVAC
  • Some individuals with altered immunocompetence may have reduced immune responses to TICOVAC
  • TICOVAC contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD). No cases of transmission of viral diseases, CJD or vCJD have ever been identified for licensed albumin or albumin contained in other licensed products
  • Vaccination with TICOVAC may not protect all vaccine recipients against tick-borne encephalitis
  • In clinical studies, the most common adverse reactions in subjects 1 through 15 years of age who received TICOVAC were local tenderness (18.1%), local pain (11.2%), headache (11.1%), fever (9.6%), and restlessness (9.1%)
  • In clinical studies, the most common adverse reactions in subjects 16 through 65 years of age who received TICOVAC were local tenderness (29.9%), local pain (13.2%), fatigue (6.6%), headache (6.3%), and muscle pain (5.1%)
  • Safety and effectiveness have not been established in pregnant women

Please see full prescribing information for TICOVAC here.

[the_ad id=”10542″]

Leave a Reply

Your email address will not be published. Required fields are marked *